Brain cells called microglia serve as the brain’s garbage crew, scarfing up bits of cellular debris. But their underperformance in aging brains contributes to neurodegeneration. Now, a possible workaround?
By blocking a protein’s activity with antibodies, Stanford University School of Medicine investigators were able to improve cognitive behavior in aging mice.
A paper describing the finding was published online April 3 in Nature. Tony Wyss-Coray, PhD, professor of neurology and neurological sciences, is the senior author. The lead author is MD-PhD student John Pluvinage
Wyss-Coray has been working for several years on the question of what causes the brain to lose its acuity with advancing age. One focus of his research has been a class of brain cells called microglia, which serve both as the brain’s immune cells and its garbage crew. Among the many different things microglia do to keep the brain healthy is scarfing up bits of cellular debris and protein deposits that build up in the course of normal metabolic activity.
On average, the garbage-collecting performance of microglia diminishes in aging brains. Why this happens, and the extent to which the faulty garbage service is actually responsible for age-related cognitive losses, are unclear. But it’s a decent bet that one way or another, microglial malperformance plays a role in neurodegeneration, said Wyss-Coray, the D. H. Chen Professor II and a senior research career scientist at the Veterans Affairs Palo Alto Health Care System.
“Many of the genes whose high-risk variants have recently been linked to Alzheimer’s disease are known to be active in the brain only in microglia,” he said. “Microglial genes’ activation patterns are abnormal in Alzheimer’s patients, and in other neurodegenerative disorders including Parkinson’s disease and amyotrophic lateral sclerosis.
“We think we may have discovered a way to get those cells back on track and make them work the way they used to when we were young.”
The ingest-then-digest procedure employed by microglia and other immune-cell types in the body is called phagocytosis. The study used laboratory techniques to identify mouse genes whose activity either impairs or enhances microglial phagocytosis and whose activity levels either increase or decrease substantially with age.
Blocking genes’ functionality
The investigators picked about 3,000 genes encoding proteins that they judged could be targeted by drugs or that had already been the focus of drug development. One at a time, they blocked each gene’s ability to encode a protein. The goal was to learn how each blockade affected the ability of cultured mouse microglia to ingest small particles of fluorescently labeled latex. (The brighter a microglial cell glowed, the better a refuse eater it was.)
“It was like examining the books of the garbage-hauling company,” Wyss-Coray said. “We wanted to know: ‘Is it the garbage truck’s faulty wheels? The rusty containers? An unanticipated garbage overflow? Lazy or poorly trained staff? Or is the street in bad shape?’”
In a parallel experiment, the investigators determined which of those approximately 3,000 genes are more or less active in microglia from the hippocampi of young mice versus old mice. (The hippocampus is a brain structure, one on each side of the brain, that’s essential to learning and memory.)
Surprisingly, when the scientists compared the results of both experiments, they found just one gene that affected microglial phagocytosis and whose activity in microglia substantially changed with advancing age. Older microglia produced far more copies of this gene — a proxy for upregulated production of the protein for which the gene is a blueprint — than younger ones did, and knocking out its function greatly improved microglial phagocytosis.
“Now we had a tentative suspect, a gene that had never before been implicated in microglial garbage removal,” Wyss-Coray said. So they zeroed in on this gene, called CD22, which is found in both mice and humans.
In a follow-on experiment, the CD22 protein turned up three times as often on the surface of older mice’s microglia as on those of younger mice’s microglia, confirming the gene-activity finding. These proteins could be blocked by antibodies, molecules that bind to a specific protein and can be generated in the lab. Antibodies are bulky and don’t easily penetrate cells, but they’re excellent for targeting cell-surface proteins.
Wyss-Coray’s team injected antibodies to the CD22 protein into the hippocampus on one side of mice’s brains. They also injected similar antibodies that were incapable of binding to CD22 into the hippocampus on the opposite side.
Along with the antibodies, the scientists administered fluorescence-labeled bits of myelin. This substance coats numerous nerve cells, for which it provides insulation. But myelin debris accumulates in aging brains and has been shown to overwhelm microglia’s ability to clear it away.
Wyss-Coray and his associates found that, 48 hours later, the myelin bits they’d injected into the mice’s hippocampi were far less prevalent on the side where they had administered CD22-blocking antibodies rather than “dummy” antibodies.
“Microglia are the only cells in mice’s brain that actually express the CD22 protein, so this difference is likely due to the CD22-blocking antibodies’ effect on microglia,” Pluvinage said.
CD22 is a new target we think can be exploited for treatment of neurodegenerative diseases.
The investigators conducted analogous experiments, substituting a protein called beta-amyloid, whose buildup in the brain is a hallmark of Alzheimer’s disease, and alpha-synuclein, another protein similarly associated with Parkinson’s disease. In both cases, microglia exposed to CD22-blocking antibodies outperformed their peers on the opposite side of the brain in ingesting the neurodegeneration-linked substances.
Then, the researchers lengthened the period of exposure from 48 hours to a full month. They reconfigured their injection technique to provide continuous CD22-blocking antibody infusion on both sides of the brain over this period. Along with a host of findings consistent with their earlier ones, Wyss-Coray’s team observed that old mice receiving these infusions outperformed control mice of the same age on two different tests of learning and memory that are commonly used to assess mice’s cognitive ability.
“The mice became smarter,” Wyss-Coray said. “Blocking CD22 on their microglia restored their cognitive function to the level of younger mice. CD22 is a new target we think can be exploited for treatment of neurodegenerative diseases.”
Stanford’s Office of Technology Licensing has filed for a patent on intellectual property associated with the study.
Wyss-Coray is a member of the Wu Tsai Neurosciences Institute at Stanford, the Stanford Maternal & Child Health Research Institute and Stanford Bio-X and a faculty fellow of Stanford ChEM-H.
The Latest on: Treatment of neurodegenerative diseases
via Google News
The Latest on: Treatment of neurodegenerative diseases
- History and progress of hypotheses and clinical trials for Alzheimer’s diseaseon August 22, 2019 at 3:11 pm
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive ... In conclusion, the current clinical drugs used for the treatment of AD improve the quality of life of AD ...
- Antisense Drugs for Huntington’s, ALS and Prion Diseases Could Meet the Dire Need for Brain Treatmentson August 15, 2019 at 4:00 am
Antisense treatments are also being investigated for prion disorders ... “But wouldn’t it be nice to have one approach that could treat a range of disorders?” Some neurodegenerative disorders linger ...
- New drug targets early instigator of Alzheimer's diseaseon August 14, 2019 at 2:15 pm
may succeed where other treatments have failed, and could be effective against a range of neurodegenerative illnesses in addition to Alzheimer's. Over a hundred years after they were first identified, ...
- Neuropore Receives Orphan Drug Designation for NPT520-34 for the Treatment of Amyotrophic Lateral Sclerosison August 14, 2019 at 5:01 am
About Parkinson’s disease Parkinson’s disease (PD) is a debilitating neurodegenerative disorder afflicting an estimated seven to ten million patients worldwide. Current treatments for PD are effective ...
- D&D Pharmatech Raises $137.1M in Series B Financing to Advance Potential Disease-Modifying Treatmentson August 14, 2019 at 4:00 am
Proceeds will be used by Neuraly to advance a clinical candidate targeting neurodegenerative diseases into Phase II studies, by Precision Molecular to advance several neuroinflammation imaging agents ...
- New Partnership to Define Neuroinflammatory Progression in Neurodegenerative Diseaseson August 13, 2019 at 6:17 am
characterization and treatment of neuroinflammation as well as definition of neuroinflammatory progression in neurodegenerative diseases. CereHealth will apply its clinical imaging experience and ...
- Spokane is fast becoming a hub for research and treatment of neurological disorderson August 9, 2019 at 2:00 pm
as well as research into better treatments and ultimately, a cure. The neurological research at the Gleason Institute will focus on ALS and other "sister" neurodegenerative diseases such as ...
- AC Immune Initiates Ph1b/2a Study of Anti-Phospho-Tau Vaccine in Alzheimer’s Diseaseon August 1, 2019 at 5:00 am
it is a key part of AC Immune's Roadmap to Successful Therapies for Neurodegenerative Diseases." By targeting specific pathological forms of Tau protein, immunization with anti-Tau vaccines has become ...
- New treatment discovered for Parkinson’s and other brain diseaseson July 30, 2019 at 2:55 am
The finding could lead to new treatments for Parkinson's and other brain ... to replace alpha-synuclein's function or boost it in people with Parkinson's disease and other neurodegenerative disorders.
via Bing News